Biotech Profiles Oxford-Harrington Rare Disease Centre – $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034 Ocugen – Targeting 300,000 RP Patients with Gene-Agnostic Modifier Therapy Platform Kindling Bio – Creating One Scalable Gene Therapy to Flag Multiple Childhood Tumors for Immune Destruction Hemispherian – First-in-Class TET2 Agonist Tackles Glioblastoma Through DNA Demethylation Citius Pharmaceuticals – From Late-Stage Development to Commercial Launch with FDA-Approved LYMPHIR™ VERIGRAFT – First Industrially Scalable Personalised Tissue Therapy Platform Advances to Pivotal Phase II GeoVax – From HIV Vaccine Pioneer to Multi-Platform Developer Targeting 40 Million Immunocompromised Americans Ciloa – First to Overcome 30-Year Challenge of Stable, Functional Recombinant Adiponectin Production One Biosciences – First clinical-grade single-cell transcriptomic platform for FFPE samples targets tumor heterogeneity gap Priothera – From Novartis Shelved Asset to Phase 3 in Five Years Alligator Bioscience – Engineering CD40 Agonism from Academic Roots to Phase 3 Readiness Minoryx – Only Brain-Penetrating PPAR-Gamma Agonist Reaches European Filing for Fatal Childhood Disease
Oxford-Harrington Rare Disease Centre – $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034
Kindling Bio – Creating One Scalable Gene Therapy to Flag Multiple Childhood Tumors for Immune Destruction
VERIGRAFT – First Industrially Scalable Personalised Tissue Therapy Platform Advances to Pivotal Phase II
GeoVax – From HIV Vaccine Pioneer to Multi-Platform Developer Targeting 40 Million Immunocompromised Americans
One Biosciences – First clinical-grade single-cell transcriptomic platform for FFPE samples targets tumor heterogeneity gap
Minoryx – Only Brain-Penetrating PPAR-Gamma Agonist Reaches European Filing for Fatal Childhood Disease
